MARLBOROUGH, Mass.,
July 21, 2016 /PRNewswire/
-- RXi Pharmaceuticals Corporation (NASDAQ: RXII), a
clinical-stage RNAi company developing innovative therapeutics that
address significant unmet medical needs, announced today that it
will present a poster at the 2016 Summer Meeting of the
American Academy of Dermatology (AAD). This meeting will
bring together the best minds in dermatology to be immersed in an
innovative program that includes presentations by renowned experts
on topics that impact dermatologists today. The Summer AAD
meeting will be held July 28-31, 2016
at the Hynes Convention Center in Boston, MA.
Logo -
http://photos.prnewswire.com/prnh/20130917/NE80755LOGO
On Friday, July 29, 2016, at
2:40 p.m. EDT, during the
Infection-Viral Poster Session, Dr. Karen
Bulock, RXi's Vice President of Research will give an oral
presentation entitled, "Diphenylcyclopropenone Ointment for the
Treatment of Common Warts". Diphenylcyclopropenone (DPCP) is a
potent topical immunotherapy agent that has been used since the
late 1970's by physicians for the treatment of common warts,
alopecia areata, and cutaneous metastases of melanoma. As
DPCP has not yet been evaluated and approved by a regulatory
agency, RXi Pharmaceuticals has developed Samcyprone™, a
therapeutic consisting of a proprietary ointment formulation of
DPCP based on technology that was licensed from Hapten
Pharmaceuticals. A summary of the proof of concept study and
an update on the status of the Company's ongoing Phase 2 study for
cutaneous warts, RXI-SCP-1502, will be provided.
The poster will be available under the "Investors –
Presentations & Posters" section of the Company's
website, www.rxipharma.com approximately 1 hour following
the presentation.
About the American Academy of Dermatology
The American Academy of Dermatology was founded in 1938. It is
the largest, most influential and most representative dermatology
group in the United States. With a
membership of more than 17,000, it represents virtually all
practicing dermatologists in the United
States, as well as a growing number of international
dermatologists. The Academy is committed to advancing the diagnosis
and medical, surgical and cosmetic treatment of the skin, hair and
nails; advocating high standards in clinical practice, education,
and research in dermatology; and supporting and enhancing patient
care for a lifetime of healthier skin, hair and nails.
About RXi Pharmaceuticals Corporation
RXi Pharmaceuticals Corporation (NASDAQ: RXII) is a
clinical-stage RNAi company developing innovative therapeutics that
address significant unmet medical needs. Building on the
pioneering work of RXi's Scientific Advisory Board Chairman and
Nobel Laureate Dr. Craig Mello, our
discovery and clinical development programs are based on our
proprietary RNAi (sd-rxRNA) platform and Samcyprone™, a topical
immunomodulator. Our clinical development programs include RXI-109,
an sd-rxRNA, for the treatment of dermal and ocular scarring, and
Samcyprone™ for the treatment of such disorders as warts, alopecia
areata, non-malignant skin tumors and cutaneous metastases of
melanoma. RXi's robust pipeline, coupled with an extensive
patent portfolio, provides for multiple product and business
development opportunities across a broad spectrum of therapeutic
areas. We are committed to being a partner of choice for academia,
small companies, and large multinationals. We welcome ideas and
proposals for strategic alliances, including in- and out-licensing
opportunities, to advance and further develop strategic areas of
interest. Additional information may be found on the Company's
website, www.rxipharma.com.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. Such statements include, but are not limited to, statements
about: our ability to successfully develop RXI-109, Samcyprone™ and
our other product candidates (collectively "our product
candidates"); the future success of our clinical trials with our
product candidates; the timing for the commencement and completion
of clinical trials; our ability to enter into strategic
partnerships and the future success of these strategic
partnerships; and our ability to deploy our sd-rxRNA® technology
through partnerships, as well as the prospects of these
partnerships to provide positive returns. Forward-looking
statements about expectations and development plans of RXi's
product candidates and partnerships involve significant risks and
uncertainties, including the following: risks that we may not be
able to successfully develop and commercialize our product
candidates; risks that product development and clinical studies may
be delayed, not proceed as planned and/or be subject to significant
cost over-runs; risks related to the development and
commercialization of products by competitors; risks related to our
ability to control the timing and terms of collaborations with
third parties; and risks that other companies or organizations may
assert patent rights preventing us from developing or
commercializing our product candidates. Additional risks are
detailed in our most recent Annual Report on Form 10-K and
subsequent Quarterly Reports on Form 10-Q under the caption "Risk
Factors." Readers are urged to review these risk factors and
to not act in reliance on any forward-looking statements, as actual
results may differ from those contemplated by our forward-looking
statements. RXi does not undertake to update forward-looking
statements to reflect a change in its views, events or
circumstances that occur after the date of this release.
Contact
RXi Pharmaceuticals Corporation
Tamara McGrillen
508-929-3646
tmcgrillen@rxipharma.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/rxi-pharmaceuticals-to-present-at-the-2016-summer-meeting-of-the-american-academy-of-dermatology-300301968.html
SOURCE RXi Pharmaceuticals Corporation